EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel Pharmaceutical Investing
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder Pharmaceutical Investing
Data Monitoring Committee Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study Pharmaceutical Investing
Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis Pharmaceutical Investing
Xanthic Biopharma Inc. Receives Conditional Listing Approval from the Canadian Securities Exchange Cannabis Investing News
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 Pharmaceutical Investing
